Physician profile
Amanda B Wilhite
NPI 1124367362
$207,067.31
in general payments reported to CMS, 2019-2025
22 companies · $71K in 2025
The $71K reported for 2025 was more than what 99% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $18K · 2022: $33K · 2023: $37K · 2024: $49K · 2025: $71K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $115K · Travel and Lodging: $22K · Food and Beverage: $10K · Consulting Fee: $8,106 · Honoraria: $744 · Education: $35.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $114,869.50 |
| Travel and Lodging | $22,236.24 |
| Food and Beverage | $10,243.47 |
| Consulting Fee | $8,106.00 |
| Honoraria | $744.00 |
| Education | $35.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $86,601.20 | 2021-2025 | Tremfya, Stelara |
| Abbvie INC. | $34,660.47 | 2021-2025 | |
| Janssen Scientific Affairs, LLC | $26,208.66 | 2021-2023 | Remicade, Stelara |
| Lilly USA, LLC | $17,410.87 | 2023-2025 | Omvoh |
| Pfizer INC. | $14,335.32 | 2022-2025 | |
| E.R. Squibb & Sons, L.L.C. | $12,315.15 | 2021-2024 | Zeposia |
| Eli Lilly and Company | $4,641.19 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $3,964.41 | 2022-2025 | Entyvio, Gattex |
| Celltrion USA INC. | $3,596.81 | 2023-2025 | Zymfentra, Vegzelma, Yuflyma |
| Celgene Corporation | $2,402.14 | 2021-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $230.35 | 2023-2025 | Dupixent |
| Genzyme Corporation | $228.09 | 2023-2025 | |
| Pharmacosmos Therapeutics INC. | $149.21 | 2023 | Monoferric |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $118.17 | 2022-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $58.56 | 2022-2024 | Dificid |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $29.69 | 2024 | Novasure |
| Ferring Pharmaceuticals INC. | $25.50 | 2022 | |
| Alcresta Therapeutics, INC. | $24.48 | 2023 | Relizorb |
| Csl Behring | $21.04 | 2025 | Kcentra |
| Phathom Pharmaceuticals, INC. | $18.67 | 2024 | Voquezna |
| Ardelyx, INC. | $13.81 | 2022 | |
| Qol Medical, LLC | $13.52 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Wilhite listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.